EASD 2018 Annual Meeting coverage

The results of the adult surgery study from the RISE consortium show that gastric banding has only a small effect on the deterioration of beta-cell function relative to metformin, despite causing markedly greater weight loss.

The PREVIEW project investigators have reported broadly positive results, but tempered by issues such as a high dropout rate.

The final version of the 2018 update to the consensus guidelines on managing hyperglycemia in people with type 2 diabetes is now published.

The addition of empagliflozin to insulin therapy reduces glycated hemoglobin levels in patients with type 1 diabetes, indicate findings from the phase III EASE-2 and 3 trials.

A compound that stimulates the receptors for both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 has dose-dependent effects on glucose levels and bodyweight in people with type 2 diabetes.

Macroalbuminuric patients with type 2 diabetes and a recent acute coronary event who are treated with lixisenatide may experience a reduction in their urinary albumin-to-creatinine ratio, suggests an exploratory post-hoc analysis of the ELIXA trial.

Results of the Harmony Outcomes trial indicate that adding the glucagon-like peptide-1 receptor agonist albiglutide to standard care may reduce cardiovascular risk among patients with type 2 diabetes and existing cardiovascular disease.

Hyperglycemia management in type 2 diabetes guidelines author Melanie Davies discusses the key updates in the 2018 edition, the evidence behind them, and the experience of being part of a trans-Atlantic consensus group (5:13).

Nurse consultant and diabetes educator Lori Berard discusses the consensus report on managing hyperglycemia in people with type 2 diabetes (2:42).

Amrit Lamba gives his view of what the updated ADA/EASD hyperglycemia guidelines mean for primary care practitioners (6:08).

Twenty years after the publication of the primary findings, medwireNews talks to longtime UKPDS investigator Professor David Matthews (University of Oxford, UK) about the struggles of the team to bring the trial to completion and the impact of the findings on diabetes care.

The UKPDS has so far generated an astonishing 93 original research papers. medwireNews​​​​​​​ rounds them up.

Professor Miles Fisher talks about the how the UKPDS shook up the treatment landscape for people with diabetes and set the stage for modern clinical research (3:13).

Researchers have used data from the UK Biobank to uncover predictors of rapid progression to insulin dependence, including pulse rate and maternal diabetes.

The recently proposed five diabetes subgroups are reproducible, but are more complicated and no better than simple clinical variables for predicting disease progression and treatment response, researchers have reported.

A single glycated hemoglobin measurement will not be sufficient to gauge treatment effects or the need for intensification in many type 2 diabetes patients, research shows.